Zofin for COPD
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine if Zofin, a new potential treatment, is safe and effective for treating Chronic Obstructive Pulmonary Disease (COPD). Participants will receive either Zofin or a placebo, along with standard care, to assess whether Zofin can better manage COPD. The trial seeks individuals with moderate to severe COPD who have not smoked for at least six months but have a history of smoking. Eligible participants must attend all follow-up visits and complete the trial assessments. As a Phase 1 and Phase 2 trial, this research focuses on understanding how Zofin works in people and measuring its effectiveness in an initial, smaller group, offering participants a chance to contribute to groundbreaking COPD treatment research.
Will I have to stop taking my current medications?
The trial requires participants to stop taking prescription or over-the-counter pain medication for 7 days before any visit. If you are on immunosuppressive medications or anticoagulation therapy that cannot be stopped, you may not be eligible to participate.
Is there any evidence suggesting that Zofin is likely to be safe for humans?
Research has shown that Zofin, administered through an IV, has been tested for safety in people with conditions like COVID-19. In these studies, most participants tolerated Zofin well, with no serious side effects directly attributed to the treatment. This suggests that Zofin might be safe for humans. However, it is still under investigation for use in people with chronic obstructive pulmonary disease (COPD), making ongoing trials crucial to confirm its safety for this condition.12345
Why do researchers think this study treatment might be promising for COPD?
Unlike the standard treatments for COPD, such as bronchodilators and corticosteroids, Zofin offers a fresh approach with its unique mechanism. Zofin is derived from extracellular vesicles, which have the potential to repair and regenerate damaged lung tissue. Researchers are excited about Zofin because it targets the underlying inflammation and tissue damage in COPD, which could lead to better lung function and improved quality of life for patients. Additionally, the treatment's administration through simple saline dilution makes it straightforward to deliver and potentially more accessible for widespread clinical use.
What evidence suggests that Zofin might be an effective treatment for COPD?
Research has shown that Zofin, which participants in this trial may receive, might help improve lung health. In an initial trial, patients who received Zofin had better lung scans and less inflammation. Another study found that 83% of patients had normal lung X-rays after treatment with Zofin. It has also been used in COVID-19 patients, where it helped reduce symptoms and improve breathing. These results suggest that Zofin could be promising for treating lung conditions like COPD.678910
Who Is on the Research Team?
Natasha Phrsai
Principal Investigator
Proxima
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive intravenous infusions of Zofin or placebo on Day 0, Day 4, and Day 8
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Zofin
Find a Clinic Near You
Who Is Running the Clinical Trial?
ZEO ScientifiX, Inc.
Lead Sponsor
Organicell Regenerative Medicine
Lead Sponsor